SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, Inc. announced today that it has initiated a collaboration with the Stanford University School of Medicine focused on developing tests to help deliver more effective therapies to cancer patients. The laboratory of Dr. Stefanie Jeffrey is utilizing Fluxion’s IsoFlux System to isolate, recover, and analyze rare circulating cancer cells at the molecular level.
